BPH (previously BioPharmica Limited) was formed in 2004 and is a listed company on the Australian Securities Exchange under code BPH. The company is commercialising a portfolio of Australian biomedical technologies emerging from research by leading Universities, Medical Institutes and Hospitals across Australia. Targeting large global markets BPH provides product development and commercial direction, whilst the institutional partner provides the majority of the infrastructure and research expertise.
Technologies on the way to commercialisation include: Diagnostic Array Systems, BacTrak a faster and more effective method of detecting infectious disease; Cortical Dynamics Brain Anaesthesia Response (BAR) Monitor - a device that measures a patient’s brain electrical activity (EEG) to indicate the response to drugs administered during surgery; HLS5 Tumour Suppress Gene a molecular marker for early and accurate cancer detection; and microtubule drugs that target the tumour vasculature.
